US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Sage Therapeutics Inc (SAGE)
Sage Therapeutics Inc (SAGE) ニュース

SAGE

Sage Therapeutics (SAGE)

Sage Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SAGE

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/23	18 : 45	PR Newswire (US)	The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE	NASDAQ:SAGE	Sage Therapeutics Inc
2024/09/19	18 : 45	PR Newswire (US)	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit - SAGE	NASDAQ:SAGE	Sage Therapeutics Inc
2024/09/17	19 : 33	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:SAGE	Sage Therapeutics Inc
2024/09/16	18 : 45	PR Newswire (US)	The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE	NASDAQ:SAGE	Sage Therapeutics Inc
2024/09/12	18 : 45	PR Newswire (US)	Sage Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE	NASDAQ:SAGE	Sage Therapeutics Inc
2024/09/06	05 : 03	PR Newswire (US)	SAGE INVESTOR ALERT: Edelson Lechtzin LLP Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action	NASDAQ:SAGE	Sage Therapeutics Inc
2024/09/05	21 : 30	PR Newswire (US)	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE	NASDAQ:SAGE	Sage Therapeutics Inc
2024/08/08	23 : 00	PR Newswire (US)	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE	NASDAQ:SAGE	Sage Therapeutics Inc
2024/08/08	05 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/08/08	05 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/08/01	05 : 15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SAGE	Sage Therapeutics Inc
2024/08/01	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/08/01	05 : 05	Business Wire	Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
2024/07/24	19 : 39	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/07/24	19 : 30	Business Wire	Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor	NASDAQ:SAGE	Sage Therapeutics Inc
2024/07/17	19 : 30	Business Wire	Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
2024/06/12	05 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/06/12	05 : 57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/06/12	05 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/06/11	19 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SAGE	Sage Therapeutics Inc
2024/06/11	19 : 30	Business Wire	Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease	NASDAQ:SAGE	Sage Therapeutics Inc
2024/06/05	19 : 30	Business Wire	Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	NASDAQ:SAGE	Sage Therapeutics Inc
2024/05/07	19 : 30	Business Wire	Sage Therapeutics to Participate in Upcoming May Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
2024/04/25	19 : 30	Business Wire	Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress	NASDAQ:SAGE	Sage Therapeutics Inc
2024/04/17	19 : 30	Business Wire	Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease	NASDAQ:SAGE	Sage Therapeutics Inc
2024/04/11	19 : 30	Business Wire	Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/28	20 : 30	Business Wire	Sage Therapeutics to Present at Upcoming March Investor Conferences	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/22	06 : 35	Edgar (US Regulatory)	Form SC TO-I/A - Tender offer statement by Issuer: [Amend]	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/16	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc
2024/02/16	07 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SAGE	Sage Therapeutics Inc

Showing the most relevant articles for your search:NASDAQ:SAGE

1 2 3 4 5 6 7 8 9 10 次へ >>

Res.mtg 15 M1 A

OMX Helsinki Telecommuni...

Republic of Italy

Ecofin Global Utilities ... (PK)

NIBC Bank NV 1% until 9/...

Credit Agricole CIB FCIA...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約